A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia
Pierre-François Laterre(Cliniques Universitaires Saint-Luc), Richard G. Wunderink(Northwestern University), Lona Poole(Novartis (Switzerland)), Steven M. Opal(Brown University), Steven P. LaRosa(Eli Lilly (United States)), Edward Abraham(New York Medical College), Abla A. Creasey(California Institute for Regenerative Medicine), Fang Xie(Yangtze University)
Cited by 45
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k